Nicotine conjugate vaccines: A novel approach in smoking cessation

Journal of the American Pharmacists Association

Volumn 52, Issue 1, 2012, Pages 116-118

  Kitchens, Caroline M ^a   Foster, Stephan L ^b  

^a Kroger   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE VACCINE; NICOTINE; NICOTINE QBETA VACCINE; VACCINE;

HUMAN; IMMUNOLOGY; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SHORT SURVEY; SMOKING CESSATION; ARTICLE; FEMALE; MALE; METHODOLOGY; SMOKING; TOBACCO DEPENDENCE; UNITED STATES;

FEMALE; HUMANS; MALE; NICOTINE; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; UNITED STATES; VACCINES;

EID: 84861217613     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.12505     Document Type: Short Survey

References (13)

1. Centers for Disease Control and Prevention. Tobacco use: targeting the nation's leading killer: at a glance 2011. Accessed at www.cdc.gov/ chronicdisease/resources/publications/AAG/osh.htm, December 6, 2011.
2. Centers for Disease Control and Prevention. Smoking and tobacco use: fact sheets. Accessed at www.cdc.gov/tobacco/data-statistics/fact-sheets/index.htm, December 6, 2011.
3. American Cancer Society. Tobacco-related cancers facts sheet. Accessed at www.cancer.org/Cancer/CancerCauses/TobaccoCancer/tobacco-related-cancer-fact- sheet, November 29, 2011.
4. Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51:642-5.
5. Food and Drug Administration. FDA 101: smoking cessation products. Accessed at www.fda.gov/forconsumers/consumerupdates/ucm198176.htm, December 6, 2011.
6. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin. 2009;5:200-5.
7. Lesage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. Accessed at www.aapsj.org/view.asp?art=aapsj080108, November 29, 2011.
8. Hall W. The prospects for immunotherapy in smoking cessation. Lancet. 2002;360:1089-91.
9. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35:2031-40.
10. Cytos Biotechnology. CYT002-NicQB: a novel vaccine for nicotine addiction. Accessed at www.cytos.com/doc/NicQb-June06-E-fv.pdf, December 6, 2011.
11. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;87:456-67.
12. Nabi Biopharmaceuticals. Clinical trials: NicVAX (nicotine conjugate vaccine). Accessed at www.nabi.com/pipeline/clinicaltrials.php, December 6, 2011.
13. ClinicalTrials.gov. Study of TA-NIC to assess the efficacy and safety of the vaccine as an aid to smoking cessation. Accessed at http://clinicaltrials. gov/ct2/show/NCT00633321, December 6, 2011.